Nuwellis Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Nuwellis Inc trades at $1.4 (market cap $542.80K), while Direxion Daily Semiconductor Bear 3X Shares trades at $40.33. Which is the better fit depends on your goals.
| NUWE | SOXS | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $220.50 | $1.49K |
52-Week Low | $1.42 | $32.50 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $39.97, down 11.59% in the past 24 hours amid a bearish technical signal. The ETF benefits from recent semiconductor sector weakness, with news highlighting its surge during chip stock sell-offs. A 1:10 stock split is scheduled for July 26, 2026, while technical indicators show oversold conditions with RSI at 26.30.
The outlook remains volatile, with SOXS positioned to gain from continued semiconductor sector pressure, though leveraged inverse exposure carries high risk. Key risks include rapid AI-driven chip rallies reversing bearish bets. Investors should weigh sector volatility against the ETF's structure, with support at $41 and resistance at $45.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →